A detailed history of Alyeska Investment Group, L.P. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 450,000 shares of GANX stock, worth $981,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
450,000
Holding current value
$981,000
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.24 - $3.99 $558,000 - $1.8 Million
450,000 New
450,000 $576,000

Others Institutions Holding GANX

About Gain Therapeutics, Inc.


  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $25.9M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.